GLUE•benzinga•
FDA Clears IND Application For Monte Rosa Therapeutics' MRT-8102, NEK7-Directed MGD Developed To Treat Inflammatory Conditions Linked To NLRP3, IL-1β, And IL-6 Dysregulation
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 10, 2025 by benzinga